Skip to main content
Equibles
IOVA logo

IOVA · Iovance Biotherapeutics, Inc. · Earnings Call Transcripts & Audio

Track IOVA — free

Use IOVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IOVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.84 +0.02 (+0.13%)
Russell 2000 member Rebalance outlook locked
Market Cap
$4.98B
Shares
452.97M
Volume · Sep 30 29.34M Avg daily vol (3M) 17.86M

Iovance Biotherapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Iovance Biotherapeutics, Inc. (IOVA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $238,000 −$106.53M '23 Q2 23-08-08 · $469,000 −$113.76M '23 Q3 23-11-07 · $715,000 −$112.98M '24 Q1 24-05-09 ▲12969.7% $31.11M −$97.10M '24 Q2 24-08-08 ▲12385.1% $58.55M −$83.54M '24 Q3 24-11-07 · $73.69M −$78.56M '24 Q4 25-02-27 ▲6798.5% $49.32M −$116.16M '25 Q1 25-05-08 ▲92.7% $59.95M −$111.66M '25 Q2 25-08-07 ▲15.2% $67.45M −$91.25M '25 Q3 25-11-06 ▲17.7% $86.77M −$71.90M '25 Q4 26-02-24 ▲44.8% $71.43M −$79.05M '26 Q1 26-05-07 LATEST ▲65.7% $99.31M −$47.31M '26 Q2 26-08-06
Conference
Investor event
2026-09-15
Iovance Biotherapeutics, Inc. (IOVA) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript
Confident tone Demand and sales momentum for AMPAG/AMTAGV Lung 202 trial enrollment and durability Forward guidance update
Revenue
$99.31M
▲ 65.7% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Iovance Biotherapeutics, Inc. (IOVA) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Confident tone Amtagvi (lifileucil) commercial growth In-house manufacturing (ICPC) Pipeline expansion across solid tumors
Revenue
$71.43M
▲ 44.8% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
Iovance Biotherapeutics, Inc. (IOVA) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Confident tone Manufacturing and operations Gross margin improvement Cash runway and financial discipline
Revenue
$86.77M*
▲ 17.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
Confident tone Lung Cancer Pipeline (LUN202) Manufacturing Centralization and Margin Improvement Community and Academic ATC Expansion
Revenue
$67.45M
▲ 15.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
Positive tone Revenue guidance and growth Manufacturing improvements Strategic restructuring and cost savings
Revenue
$59.95M
▲ 92.7% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript
Positive tone Amtagvi U.S. commercial launch Proleukin sales dynamics Q1 revenue shortfall and revised guidance
Revenue
$49.32M
▲ 6798.5% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Confident tone Amtagvi commercial launch and uptake Manufacturing capacity and supply Pipeline expansion - frontline melanoma and NSCLC
Revenue
$73.69M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
Confident tone Amtagvi commercial launch and revenue Manufacturing capacity and turnaround Gross margin outlook
Revenue
$58.55M
▲ 12385.1% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Confident tone Amtagvi U.S. Commercial Launch Proleukin Sales and Revenue Mix Pipeline and Label Expansion
Revenue
$31.11M
▲ 12969.7% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript
Confident tone Amtagvi U.S. Commercial Launch Commercial Manufacturing Capacity ATC Network Expansion
Revenue
$715,000
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Iovance Biotherapeutics, Inc. (IOVA) Q4 2023 Earnings Call Transcript
Confident tone AMTAGVI U.S. Launch Manufacturing Capacity Financial Position
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Iovance Biotherapeutics, Inc. (IOVA) Q3 2023 Earnings Call Transcript
Revenue
$469,000
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Iovance Biotherapeutics, Inc. (IOVA) Q2 2023 Earnings Call Transcript
Revenue
$238,000
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Iovance Biotherapeutics, Inc. (IOVA) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Iovance Biotherapeutics, Inc. (IOVA) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Iovance Biotherapeutics, Inc. (IOVA) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Iovance Biotherapeutics, Inc. (IOVA) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Iovance Biotherapeutics, Inc. (IOVA) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Iovance Biotherapeutics, Inc. (IOVA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Iovance Biotherapeutics, Inc. (IOVA) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Iovance Biotherapeutics, Inc. (IOVA) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Iovance Biotherapeutics, Inc. (IOVA) Q1 2021 Earnings Call Transcript
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Iovance Biotherapeutics, Inc. (IOVA) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Iovance Biotherapeutics, Inc. (IOVA) Q3 2020 Earnings Call Transcript
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Iovance Biotherapeutics, Inc. (IOVA) Q2 2020 Earnings Call Transcript
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 earnings calls
Key facts CIK 1425205 CUSIP 462260100 13F (30d) 6 filings 6 filers Visit website Investor relations